Verantos to Present High-Validity Real-World Evidence at ISPE Meeting

What's Happening?

Verantos, a leader in high-validity real-world evidence generation, is set to present its practical approaches at the International Society for Pharmacoepidemiology (ISPE) 41st Annual Meeting in Washington, D.C. CEO Dan Riskin will discuss methods to achieve fit-for-use real-world data (RWD) based on collaborations with large pharmaceutical companies and the FDA-sponsored TRUST and VERIFY studies. The presentation will focus on implementing accuracy, completeness, and traceability in data practices, using peer-reviewed methods to ensure reliability. Verantos aims to optimize data reliability, providing credible evidence for regulatory applications.

Why It's Important?

The presentation by Verantos highlights the growing importance of high-validity real-world evidence in the pharmaceutical industry. By ensuring data accuracy and reliability, Verantos supports the development of credible evidence that can accelerate clinical development, market access, and regulatory initiatives. This approach addresses the challenges of using low-quality or untested RWD, which can undermine the validity of research findings. The company's efforts contribute to the advancement of evidence-based practices in healthcare, potentially influencing policy and decision-making processes.

What's Next?

Following the presentation, Verantos may continue to collaborate with industry partners and regulatory bodies to refine its methodologies and expand its applications. The company's focus on high-validity evidence could lead to new partnerships and projects aimed at improving healthcare outcomes. As the demand for reliable real-world data grows, Verantos may play a key role in shaping industry standards and practices.

Beyond the Headlines

Verantos' emphasis on data reliability and traceability reflects broader trends in the healthcare industry towards transparency and accountability. By setting high standards for evidence generation, the company is contributing to a shift towards more rigorous and trustworthy research practices. This approach may influence other sectors to adopt similar standards, promoting integrity and confidence in data-driven decision-making.